Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
Deborah O T Alawode(UK Dementia Research Institute), Henrik Zetterberg(University of Wisconsin–Madison), Nicholas J. Ashton(King's College London), Joel Simrén(University of Gothenburg), Anniina Snellman(Turku University Hospital), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Josef Pannee(Sahlgrenska University Hospital), Ashvini Keshavan(University College London), Jonathan M. Schott(UK Dementia Research Institute), Thomas K. Karikari(University of Pittsburgh), Laia Montoliu‐Gaya(Sahlgrenska University Hospital), Amanda Heslegrave(UK Dementia Research Institute), Ross W. Paterson(Washington University in St. Louis), Johan Gobom(Sahlgrenska University Hospital), Antoinette O' Connor(UK Dementia Research Institute), Philip S.J. Weston(UK Dementia Research Institute)
Cited by 105
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k